Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
Launched by NOVARTIS · Sep 16, 2005
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Cancer patients (multiple myeloma or other solid tumors) and confirmed evidence of bone lesions
- • Significant bone pain
- • Exclusion Criteria
- • Poor renal function
- • Use of other investigational drugs within 30 days of visit 2
- • Dental or other surgery to the jaw within 6 weeks of screening, or planned during the 4 week study
- • Other protocol-defined exclusion criteria may apply.
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
Novartis
Study Chair
Novartis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials